Effects of Liraglutide 3.0 mg Injection on Weight Reduction and Metabolic Parameters for Patients Living with Obesity and Type 2 Diabetes Mellitus
Hanadi Alnageeb
Medical Department, Fujairah Hospital, Obesity Clinic, Fujairah, Emirates Health Services, UAE.
Aseilah Al Qaidy
Medical Department, Fujairah Hospital, Obesity Clinic, Fujairah, Emirates Health Services, UAE.
Ashraf Alakkad
*
Medical Department, Madinat Zayed Hospital, Al Dhafra Region, UAE.
Rania Murad
Endocrine Department, Cure Plus Medical Centre, Al Ain, UAE.
Ibrahim Mahgoub
Imperial College London, Diabetic Center, Al Ain, UAE.
Masah Mardini
Fujairah Hospital, Fujairah, Emirates Health Services, UAE.
Heba Shalabi
Fujairah Hospital, Fujairah, Emirates Health Services, UAE.
Ahmad Mhd Asim Rabih
Fujairah Hospital, Fujairah, Emirates Health Services, UAE.
Aji Gopakumar
Research Section, Emirates Health Services, UAE.
*Author to whom correspondence should be addressed.
Abstract
Background: By 2025, it is projected that one billion adults will be classified as having obesity worldwide. Unfortunately, the disease of obesity remains vastly undertreated. As an example, in the United States, nearly half of the adults meet recommendations for anti-obesity pharmacotherapy (defined as having a BMI ≥ 30, or a BMI ≥ 27 with weight-related diseases).
Owing to its impact on weight loss, remission of diabetes mellitus, and metabolic syndrome, treatment of obesity with medical therapy like Liraglutide 3.0 mg injection has offered hope for obese individuals. In recent years, obesity has increased in the UAE and the use of medical treatment for obesity has increased in-line with this trend. However, data regarding medical treatment for obesity outcomes in diabetic and non-diabetic Emirati people is scarce.
Objectives: The primary objective of the study is to evaluate the effect of Liraglutide 3.0 mg injection for weight management in patients with diabetes mellitus. In addition, we evaluated the impact of weight reduction in improving the metabolic parameters (HbA1c and LDL-c for a patient living with type2 diabetes).
Secondary objectives include improvement of infertility in females with PCOS and improvement of psychological well-being, functional capacity and quality of life. Also, we evaluated the response post-bariatric group who received Liraglutide 3.0 mg to treat their post-bariatric weight regain.
Results: In terms of weight changes, the average weight at baseline was 100.98 kg and had decreased to 97.54 kg, 96.00 kg, and 96.37 kg at 3, 6, and 12 months, respectively. Males experienced a greater rate of weight reduction than females, while diabetic patients had a lower percentage of weight loss than non-diabetic patients. Additionally, patients with PCOS were able to conceive after reducing 10% of their body weight after using Liraglutide, while the remaining 15 patients who were married but unable to conceive had an improvement in their menstrual cycle and hirsutism.
Conclusion: The results demonstrated that Liraglutide helps to induce and sustain weight loss in patients with obesity. It is an effective treatment for weight reduction and offers the unique benefit of improved glycaemic control. In addition, the study identified a correlation between weight reduction and improvements in psychological health, quality of life, and fertility in females with PCOS. Additional studies are needed to determine its long-term efficacy and safety profile.
Keywords: Type 2 diabetes, body mass index (BMI), polycystic ovarian syndrome (PCOS)
How to Cite
References
Mehta A, Marso SP, Neeland I. Liraglutide for weight management: a critical review of the evidence. Obesity Science & Practice. 2017;3(1):3-14.
Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. American psychologist. 2020;75(2):235.
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. Jama. 2016;315(22):2424-34
Obesity NAAftSo, Heart N, Lung, Institute B, Initiative NOE. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults: National Institutes of Health, National Heart, Lung, and Blood Institute …; 2000.
Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085-93.
Abdelgadir EIE, Bashier AM, Al Awadi FF, Altinay aT, Elsayed MA, Khalifa AA, et al. Liraglutide Effect on Blood Pressure, Lipids Profile, and Liver Enzymes in Arab Patients with Type 2 Diabetes Mellitus: A Prospective LIRA-BPL Study. J Diabetes Metab. 2015;6(591):2161-1122.1000591.
Nawar R, Ibrahim E, Abusnana S, Al Awadi F, Al Hammadi FH, Farghaly M, et al. Understanding the Gaps in Obesity Management in the UAE: Perceptions, Barriers, and Attitudes. Dubai Diabetes and Endocrinology Journal. 2021;27(2):37-49.
Feng P, Yu D-m, Chen L-m, Chang B-c, Ji Q-d, Li S-y, et al. Liraglutide reduces the body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. Acta Pharmacologica Sinica. 2015;36(2):200-8.
Lapolla A, Frison V, Bettio M, Dal Pos M, Rocchini P, Panebianco G, et al. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clinical therapeutics. 2015;37(3):574-84.
Chiefari E, Capula C, Vero A, Oliverio R, Puccio L, Liguori R, et al. Add-on treatment with liraglutide improves glycemic control in patients with type 2 diabetes on metformin therapy. Diabetes Technology & Therapeutics. 2015;17(7): 468-74.
Inoue K, Maeda N, Fujishima Y, Fukuda S, Nagao H, Yamaoka M, et al. Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study. Diabetology & Metabolic Syndrome. 2014;6(1):95.
Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, et al. Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovascular diabetology. 2012;11(1): 1-8.
Bashier AM, Hussain AAKB, Abdelgadir EIE, Eltinay AT, Thadani P, Abdalla ME, et al. Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial. Journal of Diabetes & Metabolic Disorders. 2015;14(1):1-7.
Mirabelli M, Chiefari E, Caroleo P, Arcidiacono B, Corigliano DM, Giuliano S, et al. Long-term effectiveness of liraglutide for weight management and glycemic control in type 2 diabetes. International Journal of Environmental Research and Public Health. 2020;17(1):207.
Nikolic D, Patti AM, Giglio RV, Chianetta R, Castellino G, Magán-Fernández A, et al. Liraglutide Improved Cardiometabolic Parameters More in Obese than in Non-Obese Patients with Type 2 Diabetes: A Real-World 18-Month Prospective Study. Diabetes Therapy. 2022;13(3):453-64.
Siamashvili M, Davis SN. Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. Expert Review of Clinical Pharmacology. 2021;14(9):1081-9.